top of page

Amylyx's Co-CEOs comment on Friday's European CHMP decision on their ALS therapy

Josh Cohen and Justin Klee give their thoughts on the negative opinion, what it means for ALS patients in Europe, and a new statistical analysis of the CENTAUR study.



Commentaires


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page